Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
暂无分享,去创建一个
O. Mir | F. Goldwasser | S. Pol | R. Coriat | S. Chaussade | J. Michels | S. Ropert | B. Blanchet | P. Boudou-Rouquette | M. Vidal | J. Durand
[1] H. Chang,et al. Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma , 2012, Oncology.
[2] O. Mir,et al. Saturable absorption of sorafenib in patients with solid tumors: a population model , 2012, Investigational New Drugs.
[3] M. Sawyer,et al. Sarcopenia in patients (pts) with hepatocelluar carcinoma (HCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Paula Ravasco,et al. Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.
[5] A. Jemal,et al. Global Cancer Statistics , 2011 .
[6] L. Birdsell,et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] L. Mccargar,et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity , 2010, Cancer Chemotherapy and Pharmacology.
[8] J. Baeyens,et al. European working group on sarcopenia in older people. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people , 2010 .
[9] F. Goldwasser,et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. , 2009, Journal of pharmaceutical and biomedical analysis.
[10] J. Soria,et al. Review Management of Hypertension in Angiogenesis Inhibitor-treated Patients , 2022 .
[11] L. Mccargar,et al. Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment , 2009, Clinical Cancer Research.
[12] K. Owzar,et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[14] Tony Reiman,et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.
[15] Tony Reiman,et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.
[16] S. Clarke,et al. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing , 2008, Expert opinion on drug metabolism & toxicology.
[17] Jeffrey W. Clark,et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. , 2007, The oncologist.
[18] F. Piette,et al. Sarcopenia is predictive of nosocomial infection in care of the elderly , 2006, British Journal of Nutrition.
[19] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.
[20] Stanley Heshka,et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. , 2004, Journal of applied physiology.
[21] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[22] S B Heymsfield,et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. , 1998, Journal of applied physiology.
[23] R. Ross,et al. Human body composition: advances in models and methods. , 1997, Annual review of nutrition.
[24] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.